Home › Compound Library › Glecaprevir/Pibrentasvir (Mavyret)

Glecaprevir/Pibrentasvir (Mavyret)

Antiviralprescriptionoral · inferred

Pan-genotypic fixed-dose combination DAA for chronic hepatitis C: glecaprevir 100 mg (NS3/4A protease inhibitor) + pibrentasvir 40 mg (NS5A inhibitor). Dose: three tablets PO once daily with food for 8 weeks in treatment-naive non-cirrhotic or compensated cirrhotic patients (12-16 weeks in treatment-experienced). Pibrentasvir terminal half-life ~23h; glecaprevir ~6h with food-enhanced absorption. SVR12 >95% across genotypes 1-6 (ENDURANCE, EXPEDITION). Contraindicated in decompensated cirrhosis (hepatic PK risk).

Projected serum levels — 3 pill (≈ 420 mg), once daily

Glecaprevir/Pibrentasvir (Mavyret)
Glecaprevir/Pibrentasvir (Mavyret) modeled serum levels, 3 pill (≈ 420 mg) once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 50 100 150 200 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 3 pill (≈ 420 mg) once daily (oral).

Modeled steady state after ~1 days: peak ≈ 159 mg, trough ≈ 8.2 mg body load. Population-based estimate over 15 days for a reference dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Antiviral
Route modeled
Oral
Model confidence
inferred
Half-life
4.9 h
Common dose
3 pill (≈ 420 mg)
Suggested maximum
3 pill/day
Reference dose range
1.5–3 pill (single dose)
Suggested cadence
once daily

Documented interactions

  • watch
    Glecaprevir + Glecaprevir/Pibrentasvir (Mavyret) Stacked effects

    Glecaprevir and Glecaprevir/Pibrentasvir (Mavyret) both push the hcv ns3 4a in the same direction.

  • watch
    Pibrentasvir + Glecaprevir/Pibrentasvir (Mavyret) Stacked effects

    Glecaprevir/Pibrentasvir (Mavyret) and Pibrentasvir both push the hcv ns5a in the same direction.

  • watch
    Sofosbuvir/Velpatasvir (Epclusa) + Glecaprevir/Pibrentasvir (Mavyret) Stacked effects

    Glecaprevir/Pibrentasvir (Mavyret) and Sofosbuvir/Velpatasvir (Epclusa) both push the hcv ns5a in the same direction.

Serum checks 3 modeled interaction pairings for glecaprevir/pibrentasvir (mavyret) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Clinical pharmacokinetics and pharmacodynamics of glecaprevir and pibrentasvir Lin CW et al. · Clinical Pharmacokinetics, 2019 DOI

    Comprehensive clinical PK/PD review of glec/pib: food-enhanced F, dose-proportional exposure, and rationale for 8-week pan-genotypic regimen.

  2. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection (ENDURANCE-1/-3) Zeuzem S et al. · New England Journal of Medicine, 2018 DOI

    Pivotal ENDURANCE trials showing >99% SVR12 with glec/pib 8 weeks in treatment-naive non-cirrhotic HCV GT1 and GT3.

2 published studies referenced in the app, each with a plain-language summary.